23 related articles for article (PubMed ID: 37691361)
1. Secondary cytoreductive surgery with and without hyperthermic intraperitoneal chemotherapy for recurrent ovarian cancer.
Lee D; Lee J; Park H; Lee YJ; Lee JY; Nam EJ; Kim SW; Kim S; Kim YT
Gland Surg; 2023 Dec; 12(12):1696-1704. PubMed ID: 38229838
[TBL] [Abstract][Full Text] [Related]
2. Cytoreductive Surgery With or Without HIPEC in the Management of Peritoneal Dissemination from Rare Histological Subtypes of Ovarian Cancer - a Retrospective Study by INDEPSO.
Sinukumar S; Damodaran D; Ray M; Prabhu A; Katdare N; Vikram S; Shaikh S; Patel A; Bhatt A
Indian J Surg Oncol; 2023 Jun; 14(Suppl 1):74-81. PubMed ID: 37359936
[TBL] [Abstract][Full Text] [Related]
3. Neoadjuvant chemotherapy for high-grade serous ovarian cancer: radiologic-pathologic correlation of response assessment and predictors of progression.
Roseland ME; Ma T; Shampain KL; Stein EB; Wasnik AP; Curci NE; Sciallis AP; Uppal S; Johnson TD; Maturen KE
Abdom Radiol (NY); 2024 Mar; ():. PubMed ID: 38478037
[TBL] [Abstract][Full Text] [Related]
4. Accuracy of CT Scan in Predicting the Surgical PCI in Patients Undergoing Cytoreductive Surgery with/without HIPEC-a Prospective Single Institution Study.
Goswami G; Kammar P; Mangal R; Shaikh S; Patel MD; Bhatt A
Indian J Surg Oncol; 2019 Jun; 10(2):296-302. PubMed ID: 31168251
[TBL] [Abstract][Full Text] [Related]
5. Tumour microenvironment characterisation to stratify patients for hyperthermic intraperitoneal chemotherapy in high-grade serous ovarian cancer (OVHIPEC-1).
Aronson SL; Walker C; Thijssen B; van de Vijver KK; Horlings HM; Sanders J; Alkemade M; Koole SN; Lopez-Yurda M; Lok CAR; ; Rottenberg S; van Rheenen J; Sonke GS; van Driel WJ; Kester LA; Hahn K
Br J Cancer; 2024 Jun; ():. PubMed ID: 38866963
[TBL] [Abstract][Full Text] [Related]
6. Unresectable peritoneal metastasis treated by pressurized intraperitoneal aerosol chemotherapy (PIPAC) leading to cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
Alyami M; Mercier F; Siebert M; Bonnot PE; Laplace N; Villeneuve L; Passot G; Glehen O; Bakrin N; Kepenekian V
Eur J Surg Oncol; 2021 Jan; 47(1):128-133. PubMed ID: 31253545
[TBL] [Abstract][Full Text] [Related]
7. [Efficacy of 1 384 cases of peritoneal carcinomatosis underwent cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy].
Yu Y; Li XB; Lin YL; Ma R; Ji ZH; Zhang YB; An SL; Liu G; Yang XJ; Li Y
Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Mar; 24(3):230-239. PubMed ID: 34645167
[No Abstract] [Full Text] [Related]
8. Long-Term Survival for Platinum-Sensitive Recurrent Ovarian Cancer Patients Treated with Secondary Cytoreductive Surgery Plus Hyperthermic Intraperitoneal Chemotherapy (HIPEC).
Petrillo M; De Iaco P; Cianci S; Perrone M; Costantini B; Ronsini C; Scambia G; Fagotti A
Ann Surg Oncol; 2016 May; 23(5):1660-5. PubMed ID: 26714958
[TBL] [Abstract][Full Text] [Related]
9. Peritoneal cancer index (PCI) based patient selecting strategy for complete cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy in gastric cancer with peritoneal metastasis: A single-center retrospective analysis of 125 patients.
Ji ZH; Yu Y; Liu G; Zhang YB; An SL; Li B; Li XB; Yan GJ; Li Y
Eur J Surg Oncol; 2021 Jun; 47(6):1411-1419. PubMed ID: 33293213
[TBL] [Abstract][Full Text] [Related]
10. Critical Analysis of Stage IV Epithelial Ovarian Cancer Patients after Treatment with Neoadjuvant Chemotherapy followed by Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (CRS/HIPEC).
Munoz-Zuluaga CA; Sardi A; Sittig M; Gushchin V; King MC; Nieroda C; Lopez-Ramirez F; Diaz-Montes TP
Int J Surg Oncol; 2020; 2020():1467403. PubMed ID: 33381312
[TBL] [Abstract][Full Text] [Related]
11. A novel treatment protocol with 6 cycles of neoadjuvant chemotherapy followed by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) in stage III primary ovarian cancer.
Marrelli D; Petrioli R; Cassetti D; D'Ignazio A; Marsili S; Mazzei MA; Lazzi S; Roviello F
Surg Oncol; 2021 Jun; 37():101523. PubMed ID: 33545658
[TBL] [Abstract][Full Text] [Related]
12. HIPEC in Ovarian Cancer: When and to Whom?
Ates O; Aksel B; Akkus MH; Oner I; Yuksel C; Dogan M
J Coll Physicians Surg Pak; 2023 Sep; 33(9):1001-1005. PubMed ID: 37691361
[TBL] [Abstract][Full Text] [Related]
13. Hyperthermic intraperitoneal chemotherapy (HIPEC) for the management of primary advanced and recurrent ovarian cancer: a systematic review and meta-analysis of randomized trials.
Filis P; Mauri D; Markozannes G; Tolia M; Filis N; Tsilidis K
ESMO Open; 2022 Oct; 7(5):100586. PubMed ID: 36116421
[TBL] [Abstract][Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]